Evidence map›Paper›PMID 30483725›Full record

ArticleInternational journal of molecular medicine2019

Isorhamnetin alleviates lipopolysaccharide-induced inflammatory responses in BV2 microglia by inactivating NF-κB, blocking the TLR4 pathway and reducing ROS generation.

Shin Young Kim, Cheng-Yun Jin, Cheol Hong Kim, Young Hyun Yoo, Sung Hyun Choi, Gi-Young Kim, Hyun Min Yoon, Hwan Tae Park, Yung Hyun Choi

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Phytochemical and Anti-Ischemic Stroke Properties from theDrug design, development and therapy · 2026
    Review
  4. Review
  5. Review
  6. Restoring AIBP expression in the retina provides neuroprotection in glaucoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Molecules (Basel, Switzerland) · 2024
    Article
  12. Molecules (Basel, Switzerland) · 2024
    Article
  13. Article
  14. Systematic Identification and Characterization ofInternational journal of molecular sciences · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. The effect ofTranslational andrology and urology · 2024
    Article
  19. Article
  20. Research advances ofFrontiers in immunology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Shin Young KimDepartment of Acupuncture and Moxibustion, Dongeui University College of Korean Medicine, Busan 47227, Republic of Korea.
Cheng-Yun JinSchool of Pharmaceutical Sciences, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China.
Cheol Hong KimDepartment of Acupuncture and Moxibustion, Dongeui University College of Korean Medicine, Busan 47227, Republic of Korea.
Young Hyun YooDepartment of Anatomy and Cell Biology, Mitochondria Hub Regulation Center, College of Medicine, Dong‑A University, Busan 49201, Republic of Korea.
Sung Hyun ChoiDepartment of System Management, Korea Lift College, Geochang, South Gyeongsang 50141, Republic of Korea.
Gi-Young KimDepartment of Marine Life Sciences, School of Marine Biomedical Sciences, Jeju National University, Jeju 63243, Republic of Korea.
Hyun Min YoonDepartment of Acupuncture and Moxibustion, Dongeui University College of Korean Medicine, Busan 47227, Republic of Korea.
Hwan Tae ParkDepartment of Physiology, Peripheral Neuropathy Research Center, College of Medicine, Dong‑A University, Busan 49201, Republic of Korea.
Yung Hyun ChoiDepartment of Biochemistry, Dongeui University College of Korean Medicine, Busan 47227, Republic of Korea.
Dong-Eui University · KRDong-A University · KRJeju National University · KRKorea Lift College · KRZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isorhamnetin, which is a flavonoid predominantly found in fruits and leaves of various plants, including Hippophae rhamnoides L. and Oenanthe javanica (Blume) DC, is known to possess various pharmacological effects. However, the anti‑inflammatory potential of isorhamnetin remains poorly studied. Therefore, the present study aimed to investigate the inhibitory potential of isorhamnetin against inflammatory responses in lipopolysaccharide (LPS)‑stimulated BV2 microglia. To measure the effects of isorhamnetin on inflammatory mediators and cytokines, and reactive oxygen species (ROS) generation, the following methods were used: cell viability assay, griess assay, ELISA, reverse transcriptase‑polymerase chain reaction, flow cytometry, western blotting and immunofluorescence staining. The results revealed that isorhamnetin significantly suppressed LPS‑induced secretion of pro‑inflammatory mediators, including nitric oxide (NO) and prostaglandin E2, without exhibiting significant cytotoxicity. Consistent with these results, isorhamnetin inhibited LPS‑stimulated expression of regulatory enzymes, including inducible NO synthase and cyclooxygenase‑2 in BV2 cells. Isorhamnetin also downregulated LPS‑induced production and expression of pro‑inflammatory cytokines, such as tumor necrosis factor‑α and interleukin‑1β. The mechanism underlying the anti‑inflammatory effects of isorhamnetin was subsequently evaluated; this flavonoid inhibited the nuclear factor (NF)‑κB signaling pathway by disrupting degradation and phosphorylation of inhibitor κB‑α in the cytoplasm and blocking translocation of NF‑κB p65 into the nucleus. In addition, isorhamnetin effectively suppressed LPS‑induced expression of Toll‑like receptor 4 (TLR4) and myeloid differentiation factor 88. It also suppressed the binding of LPS with TLR4 in BV2 cells. Furthermore, isorhamnetin markedly reduced LPS‑induced generation of ROS in BV2 cells, thus indicating a strong antioxidative effect. Collectively, these results suggested that isorhamnetin may suppress LPS‑mediated inflammatory action in BV2 microglia through inactivating the NF‑κB signaling pathway, antagonizing TLR4 and eliminating ROS accumulation. Further studies are required to fully understand the anti‑inflammatory effects associated with the antioxidant capacity of isorhamnetin; however, the findings of the present study suggested that isorhamnetin may have potential benefits in inhibiting the onset and treatment of neuroinflammatory diseases.

Indexed as

AnimalsAntioxidantsCell LineCell SurvivalCyclooxygenase 2DinoprostoneInterleukin-1betaLipopolysaccharidesMiceMicrogliaMyeloid Differentiation Factor 88NF-kappa BNitric OxideNitric Oxide Synthase Type IIQuercetinReactive Oxygen Species3-methylquercetinAntioxidantsCyclooxygenase 2DinoprostoneInterleukin-1betaLipopolysaccharidesMyeloid Differentiation Factor 88NF-kappa BNitric OxideNitric Oxide Synthase Type IIQuercetinReactive Oxygen SpeciesToll-Like Receptor 4Tumor Necrosis Factor-alpha

Identifiers

PMID30483725
PMCPMC6317673
OpenAlexW2901151076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.